specialty pharmaceuticals

The top three pharmacy challenges of 2018
The top three pharmacy challenges of 2018Find out what challenges top the list, and what analysts say can be done about them.
Will biosimilars deliver on expectations?
Will biosimilars deliver on expectations?This might be the year when it becomes clear, perhaps painfully so, whether or not biosimilars can deliver on cost savings expectations.
Autoimmune drug pipeline highlights
Autoimmune drug pipeline highlightsMore targeted therapies for autoimmune diseases are on the horizon. Here’s what to anticipate in 2018.
Managed Care State of the Industry Survey 2017As 2017 comes to a close, how do healthcare leaders feel about the state of the industry? Here’s your chance to find out.
Four therapeutic areas to watch in 2018
Four therapeutic areas to watch in 2018Prepare for major pipeline developments in diabetes, autoimmune disorders, oncology, and COPD.
Pharmaceutical pipeline: Top 4 conditions to watch
Pharmaceutical pipeline: Top 4 conditions to watchAlthough drug spend is increasing for inflammatory conditions, diabetes, and oncology, there are some promising developments in the pipeline.
Top four approaches to reduce pharmaceutical costs
Top four approaches to reduce pharmaceutical costsMCOs are fighting back against rising pharmaceutical costs. Here are the top strategies they are embracing.
Opinion: Top 2 takeaways from Asembia Specialty Pharmacy SummitThe conference raised important points about value-based contracts and the specialty pharmacy space.
Top challenges likely to slow adoption of biosimilarsBiosimilars will reshape clinical care and managed care pharmacy but ambiguities in the regulatory landscape and knowledge gaps among clinicians seem likely slow adoption.
Top considerations when determining whether to approve expensive drugsWeighing the ethics of approving expensive cancer drugs for patients facing terminal disease is a multifaceted endeavor. Here are some recommendations.